Skip to main content
padlock icon - secure page this page is secure

Antibody Epitope Exposure and Neutralization of HIV-1

Buy Article:

$68.00 + tax (Refund Policy)

Formulating an effective HIV vaccine remains a formidable challenge despite nearly 3 decades of intense research since the virus was first isolated. One of the obstacles that need to be surmounted is the design of a preparation that elicits a potent and broadly neutralizing antibody (nAb) response, i.e. antibodies with the capacity to block infectivity of the genetically diverse pool of HIV strains that circulate globally. The primary target for nAbs on HIV-1 is the envelope glycoprotein spike (Env). Early work on elucidating the exposure of antibody epitopes on Env suggested highly restricted accessibility of antibodies to epitopes that are conserved among otherwise diverse virus isolates. Crystal structures of Env-derived antigens, most in complex with antibodies, along with structure-function studies and molecular modeling, have provided significant further insight into features of Env that limit broad antibody recognition. Despite these challenges, recent progress on various fronts has led to a growing sense that Env is not as impenetrable to nAbs as might have been believed in the past. Increased understanding of antibody epitope exposure on Env should provide new impulses for efforts to elicit nAbs that can protect against HIV-1 infection.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: CCR5; CD4-binding site; CD4bs; CXCR4; Cryo-electron tomography; EBV-transformed rhesus B cells; Enfuvirtide; Env-derived antigens; Golgi apparatus; HGN194; HIV envelope glycoprotein; HIV-1; MAb b13; Neutralization; SIV/HIV chimera; V3 Region; anti-viral antibody; antibody-dependent cellular cytotoxicity; complementarity determining; cytotoxic T cells; effector cells; epitope accessibility; gp120; monoclonal antibodies; neutralization; neutralizing antibodies; neutralizing antibody; non-neutralizing antibodies; oligomerization; vaccine

Document Type: Research Article

Publication date: November 1, 2010

More about this publication?
  • Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

    Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more